Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-21
Disclosure Type: Notice of Base Price Determination Method for Relisting Due to Corporate Division
💡 3-Second Summary
Following its corporate division, the evaluated price for the surviving entity of Samsung Biologics on its KOSPI relisting date (November 24, 2025) has been set at KRW 1,221,000. The definitive opening base price for the day will be determined through a single-price auction based on buy/sell orders placed before the market opens.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Subject Entity & Reason: Surviving corporate entity of Samsung Biologics Co., Ltd. following a corporate division and subsequent KOSPI market relisting.
- Evaluated Price and Order Price Bounds for Common Stock:
- Evaluated Price: KRW 1,221,000
- Maximum Ask/Bid Limit: KRW 2,442,000 (200% of the evaluated price)
- Minimum Ask/Bid Limit: KRW 611,000 (50% of the evaluated price)
- Base Price Determination Method: Buy and sell orders are accepted within the range of the minimum limit (KRW 611,000) and maximum limit (KRW 2,442,000) from the opening of the order window until the regular market session commences. The initial price established through this single-price allocation method becomes the definitive base price for the day.
- Trading Mechanism: Once the initial base price is set via the pre-market auction, regular trading proceeds within the standard daily price limit of positive/negative 30%, identical to ordinary listed equities.
- Effective Date: November 24, 2025
- Governing Regulation: Article 30 of the Enforcement Rules of the KOSPI Market Business Regulations.
📈 2. [Expert View: What This Disclosure Means for Investors]
- Establishment of Institutional Price Framework: This regulatory notice outlines the technical parameters governing how the starting price of the surviving Samsung Biologics entity will be structured upon its return to the exchange. By securing an evaluated price of KRW 1,221,000, the exchange frames the initial boundaries for market participants, mapping out the precise playing field for day-one price discovery.
- Focus on the Price Discovery Mechanism: Unlike routine daily trading, the relisting process utilizes an opening call-auction to synthesize pre-market orders into a unified starting point. This procedure represents an administrative matching protocol native to capital market mechanics, rather than an immediate reflection of underlying fundamental adjustments like corporate revenue shifts or operational capacity changes.
- Need for Cautious Assessment: The regulatory filing does not comment on potential performance changes or financial trajectories resulting from this corporate split. Given that the pre-market order limits span a wide spectrum from KRW 611,000 to KRW 2,442,000, short-term supply and demand imbalances may introduce potential volatility at the market open. Investors are encouraged to observe the initial trading patterns objectively rather than predicting fixed price movements.
📝 Editor’s Comment (by K-STOCK Editor)
A vital technical manual detailing the opening sequence for the surviving entity of Samsung Biologics has been formalized. While the baseline valuation is anchored at KRW 1,221,000, the pre-market auction framework allows the initial opening print to land anywhere between KRW 611,000 and KRW 2,442,000 based on initial order flow. This disclosure does not serve as an operational earnings card; rather, it sets the procedural boundaries required to resume active market quotation. Because order concentrations can spark short-term price fluctuations during the opening minutes, long-term market participants may find it prudent to monitor the verified opening data calmly before modifying their allocations.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official submission data from the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
